Theralase Reports Decreased Q1 Revenue and Net Loss
Company Announcements

Theralase Reports Decreased Q1 Revenue and Net Loss

Theralase Technologies (TSE:TLT) has released an update.

Theralase Technologies Inc. has reported a 15% drop in total revenue for the first quarter of 2024 compared to the same period last year, with a notable 33% decrease in gross margin. Despite reduced revenues, the company has managed to lower its net loss by 10%, reflecting a decrease in operating expenses across various departments. A conference call is scheduled for June 6th to discuss these financial and operational results in detail.

For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskTheralase’s Rutherrin Activated by Diabetes Drug
TipRanks Canadian Auto-Generated NewsdeskTheralase Reports Decline in 2Q2024 Revenue
TipRanks Canadian Auto-Generated NewsdeskTheralase Secures Funding to Advance Cancer Research
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!